AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring
AstraZeneca CEO Pascal Soriot poses for a photograph following a television interview late last year Bloomberg
EXCLUSIVE — The ongoing R&D reorganization at AstraZeneca is claiming a group of senior executives in the company’s US R&D organization as AstraZeneca absorbs its big subsidiary MedImmune into a newly revamped global organization.
The pharma giant is handling fresh exits from Bahija Jallal’s senior leadership team at AstraZeneca’s MedImmune subsidiary — up until her departure a few weeks ago to take the CEO’s job at Immunocore in the UK, sources familiar with the latest moves tell me. More departures are expected. And current MedImmune execs have been spreading the word that the subsidiary will soon end its 11-year run as a separate organization as the company reorganizes under two previously announced main R&D banners, splitting MedImmune’s large molecule work between two disease-specific organizations.
The reorganization has sparked intense rumors about which research groups will come out on top and which will be relegated to the sidelines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.